|
Uncertainty
looms on stent manufacturers and importers
The over 150-crore Drug Eluting Stents (DES) market in India
still reeling under the jolt of Food and Drug Administration
(FDA) Maharashtra’s crackdown on “illegal”
DES at Mumbai’s JJ Hospital, now stands to witness the
unfolding of another drama as FDA-Maharashtra and Drug Controller
General of India (DCGI) lock horns debating whether DES is
a device or a drug.
Insurers
to introduce Package Deal Pricing to prevent inflated bills
In an attempt to curb inflated bills and control the abnormal
claims ratio, insurers and TPAs under the aegis of the General
Insurance Council and the Insurance Regulatory Development
Authority of India (IRDA) are about to launch ‘The Package
Deal Pricing’ (PDP), i.e. a range of prices for various
medical services and procedures.
|
